Curematch
CureMatch is a San Diego-based precision oncology company whose Decision Support System analyzes patient molecular profiles against 4.5M+ drug combinations to rank personalized cancer therapies for oncologists, cancer centers, and NGS labs.
- Company typePrivate
- Founded2015
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Curematch does
CureMatch is a San Diego-based precision oncology company, founded in 2015, that builds a clinical Decision Support System for oncologists treating solid and hematologic cancers. The platform ingests patient molecular profiling data — DNA sequencing, RNA sequencing, protein expression, and other biomarker inputs — and runs proprietary Knowledge Representation & Reasoning (KRR) algorithms against more than 4.5 million drug combinations to produce scored and ranked 2-, 3-, and 4-drug personalized combination therapy recommendations. Reports are typically delivered within 72 hours, integrate on-label, off-label, and immunotherapies, and are agnostic to the upstream NGS/tumor-profiling vendor (with integrations or partnerships including Tempus, Foundation Medicine, Guardant Health, mProbe, and Paradigm). The American Medical Association issued CPT Code 0794T for the service in 2023, enabling payer claim submission and reimbursement tracking, though insurance does not currently reimburse the service as a covered benefit.
CureMatch monetizes primarily through quote-based enterprise contracts and recurring Decision Support System subscriptions sold to cancer centers, hospital systems, NGS labs, concierge medicine providers, and individual oncology practices; patients may pay out-of-pocket using FSA/HSA funds and a financial assistance program is offered, with free reports provided for children with cancer. The company also pursues BioPharma and employer channels for clinical-trial matching and cancer-care benefits. Customer logos include UC San Diego Health, Dignity Health, Memorial Care, Johns Hopkins Hospital, Hope Health Center, and Medical University of Graz. Operations are anchored in San Diego with international touchpoints in Mexico, the UAE, Portugal, and Austria.
The company is led by CEO and Co-Founder Navid Alipour, with Chief Medical Officer Dr. Razelle Kurzrock (UCSD Moores Cancer Center) and Chief Science Officer Dr. Igor Tsigelny (formerly San Diego Supercomputer Center) as co-founders, and Dr. Stephane Richard as COO. Funding history consists primarily of two 2017 bridge rounds (led by Serra Ventures with participation from Analytics Ventures, Hera Fund, Phil Trubey, and others) and modest MetroConnect export grants; the company has not disclosed a priced Series A or any institutional growth round in available data. Strategic priorities evidenced by recent activity — CPT coding, proteomics integration, the Mark Cuban Cost Plus Drug Company collaboration, and CancerX membership — center on scaling reimbursement, multi-omic depth, and ecosystem reach.
Curematch firmographics
Firmographics- Name
- Curematch
- Legal name
- CureMatch, Inc.
- Website
- https://curematch.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CureMatch is a San Diego-based precision oncology company whose Decision Support System analyzes patient molecular profiles against 4.5M+ drug combinations to rank personalized cancer therapies for oncologists, cancer centers, and NGS labs.
- Ownership category
- akta.pro rank
Curematch industry classification
Industry- Product category
- Precision Oncology Decision Support
- NAICS
- Computer Systems Design and Related Services (54151)
- SIC
- Services-Prepackaged Software (7372), Services-Health Services (8000)
- akta.pro primary industry
- Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)
- akta.pro secondary industries
- Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF), Clinical Decision Support & Workflow Integration (EHR/oncology systems) (HLAAANAE)
Keywords
Where Curematch is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Curematch business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- Oncology Decision Support Reports: CureMatch provides scored and ranked personalized combination therapy reports to oncologists for their patients. The company charges for its Decision Support System analysis services. Reports are submitted using CPT Code 0794T for reimbursement tracking, though insurance reimbursement is not currently available.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based enterprise pricing |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
Curematch product offering
Product offeringCore offering
CureMatch operates a cloud-based Decision Support System that ingests patient molecular profiling data (DNA/RNA sequencing, protein expression) and ranks over 4.5 million possible drug combinations to surface personalized combination therapy options for cancer patients. The system delivers scored, ranked 2-, 3-, and 4-drug combination reports to oncologists within 72 hours, integrating on-label and off-label FDA-approved oncology drugs including immunotherapies, targeted therapies, and hormone therapies.
Product overview
CureMatch offers a unified precision oncology platform centered on its Decision Support System, which generates personalized combination therapy reports for oncologists. The core product analyzes molecular profiling data against over 4.5 million drug combinations to rank the most effective treatment options for individual cancer patients. The platform supports monotherapy and combination therapies of up to 4 drugs, delivers results within 72 hours, and is covered under CPT Code 0794T. CureMatch integrates genomic and proteomic data and considers immunotherapy, targeted therapy, hormone therapy, and newly approved oncology drugs in its recommendations.
Differentiator
Problem solved
Functional benefit
Brands
- CureMatch Certified Precision Oncology Recognition Award: A recognition award program to honor oncology physicians who demonstrate exceptional commitment to advancing cancer care through next-generation sequencing (NGS) and precision medicine.
Products and services
- CureMatch Decision Support System Cloud-based clinical decision support platform that analyzes patient molecular profiling data against more than 4.5 million drug combinations and produces ranked personalized combination therapy recommendations for oncologists and cancer centers.
- CureMatch Oncology Report
Quantifiable outcome
- 75% of patients treated with combination therapies based on high CureMatch matching scores showed significantly improved progression-free survival
- +3 more outcomes
Companies that use Curematch
Customer profileNamed customers7 records
Segments6 records
Ideal customer profiles4 records
Curematch technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature6 records
Curematch partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered strategic, core and minor.
- Soteria Precision Medicine Foundation (Veteran Partnership)strategicExpanded partnership to assist US Special Operations Forces veterans with cancer in identifying targeted therapies and clinical trial options in New York.
- Mark Cuban Cost Plus Drug CompanystrategicCollaboration to make cancer treatments more affordable and accessible. Patients with a CureMatch report can use Cost Plus Drugs to get lower prices on cancer medications in any combination treatment prescribed. Aligns with Cancer Moonshot initiative.
- CancerXstrategicPublic-private partnership launched by The White House as national accelerator boosting innovation in fight against cancer as part of reignited Cancer Moonshot initiative.
- mProbe Inc.corePartnership to leverage mProbe's targeted proteomics platform to assess individual proteins within patients' tumor tissues. mProbe is a CLIA-certified targeted proteomics company with proprietary technology.
- Center for Oncology in Pediatrics (COP), MexicostrategicGlobal expansion partnership as part of MetroConnect award. Extending precision medicine technology for cancer treatment in Mexico.
- SOTERIA Precision Medicine Advisory, Inc.strategicAgreement to facilitate delivery of Personalized Combination Therapy options to global cancer care community. SOTERIA provides concierge precision medicine advisory and CureMatch evaluates patient sequencing data for ranked treatment options.
- Precision Medicine Leaders SummitminorCureMatch exhibited at the Precision Medicine Leaders Summit 2017 in San Diego, showcasing decision support system to precision medicine leaders.
- JLABS-San Diego (Johnson & Johnson)coreSelected to partner with JLABS-San Diego, a Johnson & Johnson Innovation Center. Provides access to state-of-the-art equipment, facilities and operations management on the Torrey Pines mesa near La Jolla.
- UC San Diego Moores Cancer CentercoreFounding clinical partner where CureMatch was initially developed. Ongoing relationship for clinical validation, case studies, and research publications. Co-founder Dr. Razelle Kurzrock is from UCSD.
- San Diego Supercomputer CentercoreInitial development partner for computational infrastructure. CureMatch approach was developed using supercomputing power and data analytics at SDSC.
- TempuscoreTechnology partner integration. CureMatch is agnostic to tumor profiling company data and works with Tempus molecular profiling results.
- Soteria Precision Medicine FoundationstrategicExpanded partnership to assist US Special Operations Forces veterans with cancer in identifying targeted therapies and clinical trial options. Personalized cancer treatment options for veterans.
- Rady Children's HospitalminorTechnology partner listed on CureMatch website for pediatric applications.
- Dubai Health AuthoritystrategicThrough Dubai Future Accelerators program, CureMatch worked with DHA during 12-week program to setup strategic partnerships with local healthcare institutions and implement precision medicine solutions.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Curematch competitors and assessment
Company assessmentDirect peers
- Foundation Medicine: Foundation Medicine (a Roche subsidiary) provides comprehensive genomic profiling and now bundles treatment-options reporting for oncologists. Directly comparable as a molecular profiling-plus-decision-support offering, though anchored on its own sequencing assays, of which CureMatch is a partner-channel consumer.
- Tempus: Tempus is an AI-driven precision medicine company combining molecular profiling with clinical decision support for oncology. Overlaps directly with CureMatch in offering oncologists treatment recommendations derived from multi-omic patient data, but Tempus operates its own sequencing lab vs. CureMatch's lab-agnostic model.
- Guardant Health: Guardant Health is a leading liquid biopsy and molecular profiling company whose data feeds into CureMatch pipelines. Operates in precision oncology with treatment guidance capabilities, and is both a competitor in profiling-aware CDS and a CureMatch channel partner.
- Caris Life Sciences: Caris offers multi-omic molecular profiling (DNA, RNA, protein) coupled with AI-driven treatment recommendations for oncologists. Highly comparable to CureMatch in integrating genomic and proteomic data to rank therapy options, while also running its own CLIA-certified lab.
- Navican (Intermountain Healthcare): Navican is an oncology decision-support and care-navigation service offering molecular tumor board reviews and therapy recommendations to oncologists. Closely comparable in workflow, target user, and clinical positioning to CureMatch's oncology reports.
- Molecular Health: Molecular Health provides genomics-based clinical decision support, including drug-response and combination analysis for oncologists. Comparable as a software-driven precision oncology CDS vendor with EMEA presence.
- N-of-One / QIAGEN Clinical Insights: N-of-One was a molecular decision-support service matching tumor profiles to therapies and clinical trials; it was acquired by QIAGEN and integrated into QIAGEN Clinical Insights. Directly comparable to CureMatch as interpretation/decision-support atop molecular profiling data.
Broad incumbents
- Flatiron Health: Flatiron Health (acquired by Roche) builds oncology-specific EHR data infrastructure and clinical decision support for cancer care providers. Broader incumbent scope (EHR, RWE, point-of-care) that intersects with CureMatch's physician-facing decision support.
- Philips Oncology Pathways: Philips offers evidence-based oncology treatment pathways and clinical decision support embedded in oncology workflows. Broader incumbent with enterprise-wide CDS vs. CureMatch's niche molecular-combination ranking focus.
Emerging players
- Syapse: Syapse partners with health systems to operationalize precision oncology through real-world data and treatment decision workflows. Overlaps with CureMatch on precision-oncology decision support, but focused on broader data-platform deployment rather than per-patient ranking reports.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Curematch social profiles
Digital presenceCurematch compliance and trust
Trust signalCompliance1 record
Curematch financial estimates
Financial estimateRevenue estimate
Valuation estimate
Curematch leadership team
Management profileNumber of profiles
Profiles7 records
Curematch funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Curematch M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Curematch
What does Curematch do?
CureMatch operates a cloud-based Decision Support System that ingests patient molecular profiling data (DNA/RNA sequencing, protein expression) and ranks over 4.5 million possible drug combinations to surface personalized combination therapy options for cancer patients. The system delivers scored, ranked 2-, 3-, and 4-drug combination reports to oncologists within 72 hours, integrating on-label and off-label FDA-approved oncology drugs including immunotherapies, targeted therapies, and hormone therapies.
Is Curematch a public or private company?
Curematch is a private company. It is classified as venture growth investor backed and is currently operating.
When was Curematch founded?
Curematch was founded in 2015. It employs 11 to 50 people.
Where is Curematch based?
Curematch is headquartered in San Diego, United States, in the North America region.
How does Curematch make money?
One revenue line is on record: oncology Decision Support Reports.
Who are Curematch's main competitors?
Direct peers on record are Foundation Medicine, Tempus, Guardant Health, Caris Life Sciences, Navican (Intermountain Healthcare), Molecular Health and N-of-One / QIAGEN Clinical Insights. Broad incumbents are Flatiron Health and Philips Oncology Pathways. Syapse is listed as an emerging player.
Does Curematch have an API?
No public API is recorded for Curematch.
What industry is Curematch in?
Curematch's product category is Precision Oncology Decision Support. Its primary akta.pro industry code is HLACAGAH, Oncology Pathways & Precision Medicine Decision Support, with a secondary code of HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics). Its NAICS code is 54151 and its SIC code is 7372.